Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06803823 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 38 to 39 Eligibility criteria expanded, about 10 words · Secondary endpoints: details revised at 5 of 8 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 5 of 8 entries
  2. Site details revised at 5 of 38 sitesv5
  3. Study sites: 25 to 38v4
  4. Start date: Feb 1, 2025 to May 1, 2025 Study sites: 2 to 25v3 Show 1 more changeShow less
    • Study sites: 2 to 25
  5. Trial status: Not Yet Recruiting to Recruiting Primary endpoints revised (17) · Secondary endpoints revised (8) · Site details revised at 2 of 2 sitesv2 Show 3 more changesShow less
    • Primary endpoints revised (17)
    • Secondary endpoints revised (8)
    • Site details revised at 2 of 2 sites

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the efficacy and safety of ONO-2020 in patients with agitation associated with Alzheimer's Disease dementia in Japan.
Trial Details
NCT Number NCT06803823
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Conditions Agitation Associated With Alzheimer's Disease Dementia
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov